← All trials
NCT04328480
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2020
- Primary completion
- May 30, 2020
- Completion date
- Jun 30, 2020
- First posted
- Mar 31, 2020
- Last posted
- Mar 31, 2020
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Estudios Clínicos Latino AméricaLead sponsor
- McMaster UniversityCollaborator
- Estudios Clínicos Latino AméricaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.